Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Genitourinary 3Gastrointestinal 3Thoracic 2Head & Neck 2

Conditions

Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 29Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Trastuzumab 8Nivolumab 8Cisplatin 8Taxes 7Gemcitabine 7Bevacizumab 6Specimen Handling 5Oxaliplatin 5Irinotecan 5Fluorouracil 5Cetuximab 5Biopsy 5spartalizumab 4Leucovorin 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4tisotumab vedotin 3fludarabine 3durvalumab 3atezolizumab 3aldesleukin 3X-Rays 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Endometrial Neoplasms × tisotumab vedotin × Gastrointestinal × Clear all
NCT02001623 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

Phase 1/2 Completed
195 enrolled 51 charts
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03245736 2021-11-04

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

Phase 2 Completed
5 enrolled 8 charts
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT02552121 2021-04-08

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

Phase 1/2 Completed
33 enrolled 70 charts
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡